Selenoprotein p in heart failure

A heart failure and selenoprotein technology, which is applied in cardiovascular system diseases, sulfur/selenium/tellurium active ingredients, and medical preparations containing active ingredients, etc., can solve problems such as research on selenoprotein associations

Pending Publication Date: 2021-11-09
SPHINGOTEC
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The association between selenoprotein P and outcome measures has not been studied in these patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selenoprotein p in heart failure
  • Selenoprotein p in heart failure
  • Selenoprotein p in heart failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0161] Example 1: Assay Description

[0162] Selenotest ELISA ( Hybsier et al., 2017. Redox Biology 11:403-414; Hybsier et al., 2015. Perspectives in Science 3:23-24 ), a chromogenic enzyme-linked immunosorbent assay for the quantitative determination of the human selenoprotein selenoprotein P in serum samples. The Selenotest ELISA is a sandwich enzyme immunoassay performed in a 96-well plate format and uses two different selenoproteins, selenoprotein P-specific monoclonal antibodies, for the antigen capture and detection steps. Selenoprotein P levels were determined for calibrators and controls by measuring against serial dilutions of the NIST SRM 1950 standard reference material. Monoclonal antibodies (Ab) were produced by immunizing mice with an emulsion of purified recombinant selenoprotein P. The specific monoclonal antibody Ab5 was immobilized as the capture antibody, and the specific mAb2 was used as the detection antibody. The lower limit of quantitation was dete...

Embodiment 2

[0163] Example 2: HARVEST- Research

[0164] The Swedish Heart Failure Survey Study (HARVEST- ) is a Swedish Prospective, ongoing study of consecutive patients hospitalized for acute heart failure (newly diagnosed or worsening chronic heart failure). The only exclusion criterion was inability to express consent. Baseline data, including blood donation and clinical examination, were collected for 324 subjects between March 2014 and September 2018. Complete data were available for 295 patients. Data on one-year mortality (54 events), one-year cardiovascular-related mortality (44 events), and 30-day readmission (61 events) were retrieved from national and regional registries. Selenoprotein P was measured on admission, as well as a clinical examination.

[0165] clinical examination

[0166] After hospitalization, fasting blood samples were drawn, blood pressure was measured, and body mass index (BMI) was calculated in kilograms per square meter. Subjects' health status ...

Embodiment 3

[0225] Example 3: MPP Study

[0226] research description

[0227] group based The Prevention Project (MPP) is based on a Swedish single-center prospective cohort study. Between 1974 and 1992, a total of A total of 33,346 men and women of the same ethnic background in an urban area were screened for traditional risk factors for all-cause mortality and cardiovascular disease (CVD). A detailed description of the baseline procedure can be found elsewhere ( Fedorowski et al., 2010. Eur Heart J 31:85-91; Berglund et al., 1996 . J Intern Med 239:489-97 ). Between 2002 and 2006, all survivors of the original MPP cohort were invited to undergo re-examination. Of these, 18,240 participants (n = 6,682 women) responded to the invitation and underwent re-examination, including blood sampling and immediate -80°C storage of EDTA plasma aliquots. The 2002-2006 re-examination represents the baseline time point for the current study.

[0228] A random sample of 5,060 of 18,240 sub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Subject matter of the present invention is a method for assessing a risk in a subject having heart failure that is (i) the risk for getting a cardiovascular event and / or (ii) the risk of worsening heart failure condition and / or (iii) assessing the risk for mortality, in particular cardiovascular mortality, and / or (iv) assessing the risk of hospitalisation or re-hospitalisation due to having heart failure, the method comprising a) determining the level and / or the amount of Selenoprotein P and / or fragments thereof in a sample of said subject, b) correlating the determined level and / or the amount of Selenoprotein P and / or fragments thereof in a subject having heart failure with (i) the risk for getting a cardiovascular event and / or (ii) with the risk of worsening heart failure condition and / or (iii) with the risk for mortality, in particular cardiovascular mortality, and / or (iv) with the risk of hospitalisation or re-hospitalisation due to heart failure. Subject matter of the present invention includes stratification of patients and treatment methods for heart failure patients at high risk (i) for getting a cardiovascular event and / or (ii) of worsening heart failure condition and / or (iii) for mortality, in particular cardiovascular mortality, and / or (iv) of hospitalisation or re-hospitalisation due to heart failure.

Description

technical field [0001] The subject of the present invention is a method for assessing the risk of (i) a cardiovascular event and / or (ii) a worsening of the heart failure condition in a subject suffering from heart failure and and / or (iii) risk of death, especially cardiovascular death, and / or (iv) risk of hospitalization or rehospitalization due to heart failure, said method comprising [0002] a) determining the level and / or amount of selenoprotein P and / or fragments thereof in a sample of said subject, [0003] b) correlating the determined levels and / or amounts of selenoprotein P and / or fragments thereof in subjects with heart failure with the risk of (i) developing a cardiovascular event and / or (ii) Risk of worsening heart failure condition and / or (iii) risk of death, especially cardiovascular death, and / or (iv) risk of hospitalization or rehospitalization due to heart failure. [0004] The subject of the present invention includes stratification of patients and methods ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68A61K31/00
CPCG01N33/6893G01N2800/325G01N2800/50A61K33/04A61P9/04
Inventor 安德烈亚斯·贝格曼奥勒·米兰德马丁·芒努松
Owner SPHINGOTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap